苦諦

生苦、老苦、病苦、死苦，憂悲惱苦、怨憎會苦，恩愛別離苦、所欲不得苦。取要言之：五盛陰苦，是謂名為苦諦。

－增一阿含經，佛告五比丘

誰說我不在乎

高明駿與陳艾湄的經典情歌，當年是一首機車(光陽DJ1RR)廣告的主題曲，廣告裡年輕、娃娃臉的郭富城被生氣的女友潑了一臉的水，女友轉身坐火車離開，帥氣的郭富城騎上機車超越火車提前到火車站等女友，女友出站看到郭富城臉上無辜又認真的表情，不禁浮起甜蜜微笑。郭富城這個廣告以及後來的"你是我的巧克力"廣告不知迷倒了多少當年的懷春少女。

 

原版廣告的收錄音效實在令人不敢恭維，這裡找到一首高音質的原曲，真是好聽。記得當年喜歡聽這首歌，還刻意模仿高明駿那獨特沙啞嗓音，自己二部輪唱唱得不亦樂乎呢 ！

誰說我不在乎
作詞：小軒　作曲：譚健常　女聲：陳艾湄

（男）一封不該來的信　你又何必介意
昨天的你變得好模糊　真叫人捉不住
（女）捉不住的是你的心　不是我太在乎
在她信中你對她好溫柔　你怎麼解釋清楚

※（合）為什麼　感情變得好脆弱
（男）我不想感情介入第三者　oh～No
（合）難道一生的承諾（男）輕易在誤解中錯過
（女）輕易在抉擇中失落
（合）讓心中難圓的夢伴隨你我

（男）猜不透的是你的心
（女）誰說我不在乎
（合）昨天的你變得好模糊　難道只為了一封信
（合）昨天的你變得好模糊
（合）難道只為了一封信

(轉載) 翹翹板

很有道理不是嗎？給原創作者拍拍手吧！

暗黑版結局~~

原出處：粉紅兔子窩

 

生技公司未來的新商業模式：獨立生存、長期營運

Mass. biotech firms urged to remain independent

 

By Robert Weisman       Globe Staff / October 7, 2009

It’s time for pulling up the bootstraps.

That was the message delivered to biotechnology start-ups at the 11th annual MassBio Investors Forum yesterday. At a time when major drug makers are consolidating and may be less willing to buy fledgling companies, biotechs have to make it on their own and bring drugs to market themselves.

Industry leaders warned that the old model of forming a biotech company, shepherding a drug through development and years of clinical trials, and then selling the company to a pharmaceutical buyer may be played out.

Success will now require a survival mentality and a focus on remaining independent, said Barry Greene, president of Cambridge biotech Alnylam Pharmaceuticals Inc.

“Cultures that depend on survival are absolutely critical for this industry to succeed,’’ Greene said. “If you don’t want to [stay independent], you’re not a company. You’re a project.’’

Biotech leaders said it could take seven to 10 years to bring new drugs into commercial use in the future, compared with the five- to six-year time horizon of the past, mostly because of scarcer financing and a longer government approval process.

James J. O’Mara, vice president of business development at another Cambridge biotech, Ironwood Pharmaceuticals Inc., said more start-ups are willing to invest in technology without the expectation they will be snapped up for a premium. If the technology doesn’t lead to a product, they must be ready to shut down and cut their losses, he said. “People are being much more explicit about the company they’re building, and I think that’s a good thing,’’ O’Mara said.

During a panel on building a sustainable biotech business model, moderator Ted Torphy, chief scientific officer and head of external research for Johnson & Johnson Pharmaceuticals, told the audience at the Sheraton Boston Hotel that drug companies continue to look to biotechs for research and development.

“As an industry, we’re spending more and more for less and less productivity,’’ Torphy conceded. “Unless this changes, large pharmaceutical companies may be doing better by their shareholders if they invest in oil rather than investing in drug discovery.’’

But that doesn’t mean they are as ea ger to make acquisitions as they’ve been in the past, Torphy said, noting that big pharmaceutical companies have been moving aggressively to pare costs by streamlining research and striking partnerships with biotechs. “We want products, we don’t want companies,’’ he said.

Not everyone agreed the old business model is broken.

Alan Crane, former chief executive of Momenta Pharmaceuticals in Cambridge who is now general partner at Polaris Venture Partners in Waltham, said biotechs that focus on developing “breakthrough technology’’ rather than finding new ways to use old technology will get funding despite the retrenchment at pharmaceutical companies.

“There’s a lot of reason for long-term optimism,’’ Crane said, citing the aging of the population and growth in global markets.

The most successful companies will be innovators, said Katrine Bosley, chief executive of Avila Therapeutics in Waltham .

“One way you know that you’re innovating is if everybody thinks you’re crazy,’’ Bosley said. “If you’re not getting that kind of reaction on a regular basis, then you’re not being innovative enough.’’

But in the near future, biotechs will operate in an environment of funding scarcity and will need to adjust their goals - and their “burn rates,’’ the speed at which they run through venture capital - said Noubar Afeyan, managing partner and chief executive of Flagship Ventures in Cambridge.

He defended venture capital firms’ practice of investing in more mature companies, which has come under criticism from cash-starved entrepreneurs. “If we pour a lot of money into the early stage, we’re going to have a lot of orphan companies.’’

 

媽媽歌

天啊！跟我每天對著小孩碎碎念的內容幾乎一樣..........................

It's so touching!

腳步加速的那一秒，牠知道................最愛牠的人回來了。What is love? This lion can tell you.



上面的連結已失效，請參考下面連結：(2013-06-18更新)

涅槃 (Nirvana)

一段不可思議的涅槃(Nirvana)與極樂(Euphoria)的體驗。是否達到涅槃與極樂其實意味著以意識抑制左腦的運作，並讓右腦徹底控制一切的一種感覺？

**************************************************************************************

你腦內的兩個世界(中文) -- 吉兒泰勒(Jill Bolte Taylor)